Navigation Links
Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
Date:4/15/2011

ction of the BLA by the end of this year, which will complete the application. If approved, metreleptin would be the first therapy indicated specifically for the treatment of diabetes and high triglycerides in patients with lipodystrophy, and the first approved therapeutic use of metreleptin.

About Amylin Pharmaceuticals, Inc.

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

This press release contains forward-looking statements about Amylin which involve risks and uncertainties.  The actual results for Amylin could differ materially from those discussed due to a number of risks and uncertainties, including that the CMC section of the metreleptin BLA mentioned in this press release may not be submitted in a timely fashion, the estimate of the number of lipodystrophy patients mentioned in this press release may not be accurate, clinical trials or studies may not start when planned, confirm previous results, be predictive of real world use or achieve intended clinical endpoints; preclinical studies may not be predictive; our product candidates, including the product candidate mentioned in this press release, may not receive regulatory approval; and inherent scientific, regulatory and other risks in the drug development and commercialization process. These and additional risks and uncertainties are described more fully in Amyli
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), ... that its VENTANA System for Primary Diagnosis 1 ... Union for routine pathology, including primary diagnosis with ... Virtuoso software coupled with either the VENTANA iScan ... provides automated digital slide creation, case management and ...
(Date:8/20/2014)... BURLINGTON, Mass. , Aug. 20, 2014 ... Japanese electrophysiology (EP) mapping and ablation device ... increasingly use ablation to treat atrial fibrillation ... a primary treatment option for AF will ... for this application, such as advanced loop ...
(Date:8/20/2014)... 2014  Amerigen Pharmaceuticals Ltd. announces that its ... received Chinese FDA (CFDA) approval and has subsequently ... the China domestic market.  ... agreement with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen ... approved and China CFDA certified oral solid dose ...
Breaking Medicine Technology:Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2
... Sequenom, Inc. (Nasdaq: SQNM ) today announced ... company at the following conferences in November. ... ) Lazard Capital Markets 7th Annual ... York, NY Presentation date: Tuesday November 16, 2010 ...
... Pharmaceuticals today announced it has discovered that EVP-6124, its ... not previously seen in the scientific community: it acts ... By acting as a co-agonist and sensitizing ... amounts of naturally occurring ACh, typically found in individuals ...
Cached Medicine Technology:Sequenom to Present at Two Financial Conferences in November 2EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 2EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 3
(Date:8/20/2014)... made it easier to predict both breast cancer ... of a unique gene. The newly found marker ... and customise a treatment regimen that is more ... scientists from A*STAR,s Institute of Molecular and Cell ... Singapore (CSI Singapore) at the National University of ...
(Date:8/20/2014)... The Institute for Integrative Nutrition ... to announce its new partnership with California ... university offering graduate programs featuring flexible learning. Graduates ... now eligible to receive six graduate credits towards ... , “I’m so thrilled to announce this new ...
(Date:8/20/2014)... "I decided that there needed to be a ... without the hassles associated with using conventional oral devices," ... DR. GATES ORAL-HYGIENE TOOL provides an easy way to ... oral hygiene and fresh breath, and it eliminates the ... eco-friendly and easy to use, the device is producible ...
(Date:8/20/2014)... extracted acellular allogeneic nerve, from which Schwann ... been removed, reduced postoperative immune rejection. Simultaneously, ... substrates and base materials, such as the ... provide a good scaffold in the process ... nerve, similar to autologous nerve transplantation, can ...
(Date:8/20/2014)... 20, 2014 Doctors at the University of ... out mesothelioma in laboratory mice by injecting them with a ... details of the study on its website. Click here ... Hong Kong University’s AIDS Institute of Microbiology created a vaccine ... PD-1. By altering DNA, the vaccine is designed to prevent ...
Breaking Medicine News(10 mins):Health News:Novel gene predicts both breast cancer relapse and response to chemotherapy 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 3Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2
... cuts side effects , , MONDAY, May 11 (HealthDay ... mesylate (CM) to the conventional two-drug regimen of ... vomiting (CINV) in patients undergoing highly emetogenic chemotherapy ... used to treat many types of solid tumor ...
... DNA offers insights to better treatments, scientists say , , ... studies have identified what researchers describe as a treasure ... "In one fell swoop, to find so many genes ... the lead author of one of the studies, Dr. ...
... for People with Epilepsy Now Accepting EntriesTITUSVILLE, N.J., May ... for centuries, with most agreeing that art means something ... can be a self-expressive, visual demonstration of how it ... Expressions of Courage (R) is a national contest for ...
... mild , , MONDAY, May 11 (HealthDay News) -- Confirmed ... to more than 2,500 by Monday, and the U.S. now ... according to World Health Organization figures. , The number of ... the weekend, with health officials in Washington state reporting late ...
... MedCath Corporation (Nasdaq: MDTH ), ... services, predominately the diagnosis and treatment of cardiovascular ... its senior management team as Senior Vice President, ... hospitals located in Arizona, California, New Mexico as ...
... Shaver, will be an invited panelist in the second annual SOA in ... Illinois. , ... Plano, Texas (PRWEB) May 11, 2009-- Corepoint Health,s CTO, ... in Healthcare conference to be held on June 2 - 4 in ...
Cached Medicine News:Health News:3-Drug Combo Reduces Nausea After Chemo 2Health News:Genes Yield Clues to High Blood Pressure 2Health News:Genes Yield Clues to High Blood Pressure 3Health News:Every Picture Tells A Story, Particularly for Those With Epilepsy 2Health News:Every Picture Tells A Story, Particularly for Those With Epilepsy 3Health News:U.S. Now Leads World in Swine Flu Cases 2Health News:U.S. Now Leads World in Swine Flu Cases 3Health News:U.S. Now Leads World in Swine Flu Cases 4Health News:U.S. Now Leads World in Swine Flu Cases 5Health News:U.S. Now Leads World in Swine Flu Cases 6Health News:U.S. Now Leads World in Swine Flu Cases 7Health News:U.S. Now Leads World in Swine Flu Cases 8Health News:U.S. Now Leads World in Swine Flu Cases 9Health News:U.S. Now Leads World in Swine Flu Cases 10Health News:U.S. Now Leads World in Swine Flu Cases 11Health News:David Covert to Join MedCath as Senior Vice President, Operations 2Health News:Corepoint Health CTO to Participate in Panel Discussion at the 2009 SOA in Healthcare Conference 2Health News:Corepoint Health CTO to Participate in Panel Discussion at the 2009 SOA in Healthcare Conference 3
Stylish yet conservative, these classics are reliable, comfortable and durable....
Safilo Design, a state-of-the art ophthalmic collection that blends technology with minimalist sophistication. Each style comes with a sleek silver-colored hard case with magnetic closure....
Inquire...
Classic, stylish, and preppy, this collection features men's, women's and unisex styles....
Medicine Products: